Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MTTP | P55157 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448518 | 1.00 | L3MBTL1 (0.54) | L3MBTL1NR1H4KCNK9RAB9ALMNA | |
| SCHEMBL4452601 | 0.90 | L3MBTL1 (0.44) | L3MBTL1NR1H4KCNK9RAB9ALMNA | |
| SCHEMBL4452596 | 0.90 | L3MBTL1 (0.44) | L3MBTL1NR1H4KCNK9RAB9ALMNA | |
| SCHEMBL13960116 | 0.87 | CTSL (0.48) | L3MBTL1NR1H4KCNK9RAB9ALMNA | |
| SCHEMBL4456080 | 0.86 | DGAT1 (0.43) | L3MBTL1LMNAALDH1A1HDAC1NPC1 | |
| SCHEMBL4456084 | 0.86 | DGAT1 (0.43) | L3MBTL1LMNAALDH1A1HDAC1NPC1 | |
| SCHEMBL4445027 | 0.86 | HPGDS (0.59) | L3MBTL1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4445032 | 0.86 | HPGDS (0.59) | L3MBTL1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4456912 | 0.85 | KDM4E (0.55) | LMNAALDH1A1NPC1 | |
| SCHEMBL4456906 | 0.85 | KMT2A (0.49) | L3MBTL1LMNAALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | L3MBTL1 1802/4885NR1H4 2049/4885KCNK9 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.